Paper Details

  1. Home
  2. Paper Details

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.

Author: DuelandSvein, GrønbechJon Erik, HoemDag, LaboriKnut Jørgen, LassenKristoffer, MortensenKim, SmaalandRune, SorbyeHalfdan, SøreideJon Arne, VerbekeCaroline

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Pancreatic cancer is a serious disease. While surgery is the main treatment, chemotherapy given before or after surgery can improve survival. The NorPACT-1 study is investigating whether giving chemotherapy before surgery in people with resectable pancreatic cancer can reduce the number of deaths within one year of starting treatment.
Paper Details　
Original Abstract of the Article :
Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains the foundation for potentially curative treatment, survival benefit is achieved with adjuvant oncological treatment. Thus, completion of multimodality treatment (surgical resection and (neo)adjuva...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389186/

データ提供：米国国立医学図書館（NLM）

Neoadjuvant Chemotherapy for Pancreatic Cancer: A Promising Path

In the vast desert of cancer research, pancreatic cancer stands as a formidable foe, often presenting a challenging therapeutic landscape. This study, akin to a determined camel caravan seeking a route through treacherous dunes, outlines a clinical trial (NorPACT-1) to investigate the potential benefits of neoadjuvant chemotherapy for resectable pancreatic cancer. The researchers aim to determine whether neoadjuvant chemotherapy, administered before surgery, can improve survival rates and offer a more effective treatment approach. The study highlights the growing emphasis on multimodality treatment strategies in tackling this aggressive disease.

A New Approach to Fighting Pancreatic Cancer

The NorPACT-1 trial seeks to evaluate the effectiveness of neoadjuvant chemotherapy, administered before surgery, as a potentially more effective treatment strategy for resectable pancreatic cancer. The trial's findings may provide valuable insights into the role of multimodality treatment in improving survival outcomes for patients with this challenging disease.

Navigating the Dunes of Pancreatic Cancer

Pancreatic cancer remains a formidable challenge, but ongoing research efforts, like the NorPACT-1 trial, offer hope for improved treatment strategies. By exploring the potential benefits of neoadjuvant chemotherapy, researchers are seeking to navigate the treacherous dunes of this disease and improve the survival rates for those affected.

Dr.Camel's Conclusion

The NorPACT-1 trial represents a beacon of hope in the challenging desert of pancreatic cancer research, seeking to illuminate a path towards improved treatment strategies and survival outcomes. The study's findings have the potential to significantly impact the management of this aggressive disease, offering a more effective approach for those navigating the treacherous terrain of cancer.
Date :
  1. Date Completed 2018-03-19
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

28841916

DOI: Digital Object Identifier

PMC6389186

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.